Bloomberg Law
Free Newsletter Sign Up
Bloomberg Law
Welcome
Go
Free Newsletter Sign Up

2 Experimental Ebola Treatments Seen Improving Survival Odds (1)

Aug. 12, 2019, 3:18 PMUpdated: Aug. 12, 2019, 4:34 PM

Ebola treatments developed by Regeneron Pharmaceuticals Inc. and the NIH have shown to work better than Mapp Biopharmaceutical Inc.'s ZMapp, the NIH announced Aug. 12.

A clinical trial testing four potential Ebola treatments during the current outbreak in the Democratic Republic of the Congo found patients who received Regeneron’s REGN-EB3 and another one known as mAb114 had a greater chance of survival compared with the other two study arms.

A board monitoring the safety data recommended scientists stop the study early and that all future patients receive either REGN-EB3 or mAb114 in what is being considered an extension phase of ...